Abstract
Elevated Lp(a) levels are causal, independent predictors of CVD and aortic stenosis (AS). Specific therapies to potently lower Lp(a) are lacking. We assessed the safety and efficacy of ISIS-APO(a)Rx in patients with elevated Lp(a) and of ISIS-APO(a)-LRx, an optimized antisense oligonucleotide (ASO)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
